Skip to main content

Giovannino Silvestri, PhD

Academic Title:

Research Associate

Primary Appointment:

Medicine

Additional Title:

Research Associate at Institute of Human Virology, Division of Virology, Pathogenesis and Cancer (VPC)

Location:

Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, Laboratory of Stem Cell & Cancer Biology

Phone (Primary):

tel:410-706-6168

Education and Training

2003-2006, B.S., Biology, University of Calabria, Italy.             

2006-2009, M.S., Biology, University of Calabria, Italy (Magna cum Laude).   

2010-2013, Ph.D.,Molecular and Cellular Biology and Pathology, University of Verona, Italy. Thesis Advisor – Dr. Claudio Sorio.“Biochemical and functional characterization of the oncosuppressor gene Protein Tyrosine Phosphatase Receptor Gamma in Chronic  Myelogenous Leukemia”.

2013-2018, Post-Doctoral Fellow, Program in Oncology, University of Maryland, Greenebaum CCC, Baltimore, USA.

2018-2018, Research Associate, Program in Oncology, University of Maryland, Greenebaum CCC, Baltimore, USA.

2019- Present, Research Associate, Institute of Human Virology, University of Maryland, Baltimore, USA.

Biosketch

Dr. Giovannino Silvestri received his M.S. in Pathology and Molecular Biology (Summa cum laude) from the University of Calabria in 2009, Italy. In 2013, he earned his Ph.D. in Molecular and Cellular Biology and Pathology from the University of Verona, Italy, working in Dr. Sorio’s laboratory on assessing the role of the Protein Tyrosine Phosphatase Receptor Gamma (PTPRG)  in Chronic Myelogenous Leukemia (CML). Dr. Silvestri's research has been dealing with malignant hematology since 2009. His interest has been focused for the past ten years on understanding the molecular mechanisms responsible for the emergence, maintenance and progression of leukemias in particular on CML. In 2013, he joined Prof. Perrotti’s laboratory at University of Maryland Baltimore (UMB), Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD, USA where he is studying the role of miRNAs in the cross-talk between leukemic stem, stromal and immune cells. Dr. Silvestri has broad background in the molecular biology of cancer with specific training in chronic myelogenous leukemia (CML) research. During the few years spent in the USA, he  focused  his efforts in identifying novel mechanisms of stemness in CML. Dr. Silvestri’s research interest is on the role of non-coding RNAs as regulators of normal and leukemic stem and progenitor cell function and to develop new therapeutic drugs that will improve outcome of CML patients resistant to tyrosine kinase inhibitor-based therapies and eradicate the disease at stem cell level.

Currently, in Dr. Rathinam Lab at The Institute of Human Virology, he is actively engaged in the identification of signal transduction pathways that contribute to the transformation of Normal Hematapoietic Stem Cells into Leukemia Stem Cells. In addition, he focuses on the importance of post-translational modifications of signal transducers in the phenomenon of Leukemic transformation using mouse models.

 

Research/Clinical Keywords

Hematology Malignancies, Chronic Myeloid Leukemia, Ph+ALL, Tumor Microenvironment, MicroRNAs, Non-long coding RNAs, Signal Transduction, mouse models.

Highlighted Publications

  1. Bellisola G., Cinque G., Vezzalini M., Moratti E., Silvestri G., Redealli S., Gambacorti Passerini C., Wehbe K., and C. Sorio. Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis, Analyst, 138:3934-3945, 2013.

  2. Bellisola G, Bolomini Vittori M, Cinque G, Dumas P, Fiorini Z, Laudanna C, Mirenda M, Sandt C, Silvestri G, Tomasello L, Vezzalini M, Wehbe K, Sorio C. Unsupervised explorative data analysis of normal human leukocytes and BCR/ABL positive leukemic cells mid-infrared spectra. Analyst,140:4407-22, 2015

  3. Perrotti D, Silvestri G, Stramucci L. Chronic Myelogenous Leukemia (CML): Current Research Focus. The Hematology Journal, 9:91-102, 2015.  

  4. Laidlaw K., Berhan S., Liu S, Silvestri G, Holyoake T, Frank D, Aggarwal B.B., Perrotti D., Jørgensen H., Arbiser J. Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 7:51651, 2016.

  5. Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in Chronic Myeloid Leukemia: the leukemic stem, progenitor and stromal cell interplay. Current drug targets, 18:377-388, 2017.

  6. Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D and Machova Polakova K. BCR-ABL1 mediated miR-150 downregulation throught MYC contributed to myeloid differentiation block and resistance in chronic myeloid leukemia. Haematologica, 103(12):2016-2025. doi: 10.3324/haematol.2018.193086, 2018.

  7. G Silvestri, R Trotta, L Stramucci, JJ Ellis, JG Harb… -Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions, Blood Cancer Discovery,, 2020.

  8. *Palma G, *Pasqua T, Silvestri G, Rocca C, Gualtieri P, Barbieri A, De Bartolo A, De Lorenzo A, Angelone T, Avolio E and Botti G. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19, Frontiers in  Immunology. 11:2094. doi: 10.3389/fimmu.2020.0209, 2020. *equally contributed. 2020.

  9.  Benedetti*, F.; Silvestri*, G.; Nartuhi*, C.M.; Weichseldorfer, M.; Cash, M.N.; Dulcey, M.; Vittor, A.Y.; Ciccozzi, M.; Salemi, M.; Latinovic, O.S.; et al. Retinoic acid stimulation of human neuronal cells increases SARS-CoV-2 receptors expression and Spike-mediated entry. Microorganisms.*equally contributed. (under review) 2021.

 

Awards and Affiliations

Memberships:

2014-present   Member, American Society of Hematology (ASH).

2015-present   Member, American Association for the Advancement of Science (AAAS).

2015-present   Member, The International CML Foundation (iCMLf)

2017-present   Associate Member, American Association for Cancer Research (AACR).

 

Honors and Awards:

2009, Best Graduate Award 2009, University of Calabria, Italy, awarded for distinguished  performance in biology.

2010-13, Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona, Italy.

2012, 14th ESH-iCMLf Travel Award, Baltimore, USA.

2014, 16th ESH-iCMLf Travel Award, Philadelphia, USA.

2015, Nominated by Dr. Albert Reece, MD, PhD, MBA, John Z. and Akiko K. Bowers Distinguished Professor and Dean of the School of Medicine, University of Baltimore, to partecipate in the AAAS/Science Program for Excellence in Science. This program rewards deserving graduate students, medical students, and postdocs working in the life sciences, Baltimore, USA.

2015, Award for Best poster presentation, University of Maryland, USA.

2015, American Society of Hematology Abstract achievement Award winner, Orlando, USA.  

2017, September Postdoc Appreciation Month, program in Oncology, University of Maryland, USA.

2018, Member Memory Board and Membership Testimonial, Selected from The American Association for Cancer Research (AACR), Chicago, USA.

Grants and Contracts

Grant Reviewer:

2021, Health Research Council of New Zealand (HRC)

 

Pending Applications:

 2022, Vilcek Prizes for Creative Promise in Biomedical Science

PI: Silvestri

 

Ongoing Research Support:

NIH/NHLBI 1R01HL132194       02/15/2017-01/31/2023

PI: Rathinam

Role: Key personnel

Title: NF-KB signaling in the control of Hematopoiesis. The goal of this project is to assess the precise role of NF-KB in hematopoietic stem cells that would be essential to understand and treat hematopoietic diseases that arise due to defective NF-KB activation.

 

Completed/Ended Research Support:

NIH/NCI R01CA163800             01/31/2012-01/31/2019

PI:Perrotti

Role: Key personnel

Title: Role of microRNAs in the regulation of CML stem cell survival and self-renewal.

The goal of this project is to assess the role of microRNAs targeting in a canonical or decoy manner the BCR- ABL1/Jak2/SET-PP2A/b-catenin pathway in survival/self-renewal of leukemic stem and progenitor cells.

 

NIH-NCI 1R21CA209183-01       07/13/2016-06/30/2019

PI: Perrotti

Role: Key Personnel

Title: Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia.

The goal of this project is to assess the role of SETBP1 and that of the PP2A inhibitory complex in the survival and self-renewal of Ph+ B-ALL stem cells.

 

Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona, Italy       01/01/2010-05/30/2013

PI: Silvestri

 

 

In the News

  1. Dr Silvestri  on March 11th, 2019 released an interview to an italian science magazine OGGIScienza.it that interviewed him to tell to the italian community the research he is performing in the United States of America. https://oggiscienza.it/2019/03/11/leucemia-mieloide-cronica/Chronic myeloid leukemia, the research to destroy cancer stem cells. Two directions of CML research: study drug-resistant cancer stem cells and develop new molecules to treat patients resistant to therapies by Luisa Alessio. 11 March 2019.
  2. Chronic myelogenous leukemia (CML) is a stem cell disorder once considered an eventual death sentence upon progression to the terminal acute/blastic cell phase, a  terrible clinical outcome that has improved with the introduction of tyrosine kinase inhibitors. A major continuing problem with treating CML is the persistence of drug-resistant leukemia stem/initiating cells (LS/IC).In the first issue of Blood Cancer Discovery, Silvestri and colleagues describe an incredibly in-depth mechanistic study using genetic and pharmacologic modulation of the miRNA MiR300 with and without treatment with activators of the serine-threonine protein phosphatase 2A (PP2A) in human cells. In vitro studies and in vivo mouse models of patient-derived xenografts were used to address the need to target LS/ICs and restore immunity of impaired natural killer cells for attenuation of CML progression. Spotlight by Hal Broxmeyer. https://bloodcancerdiscov.aacrjournals.org/content/1/1/13. July 2020.

 

Professional Activity

2012, MicroFTIR stage and performing experiments at the Synchrotron Soleil, Paris, France.

2013, Organized laboratory planning and maintenance, University of Maryland, USA.   

2015, Mentor laboratory for The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research at Universityof Maryland Baltimore Greenebaum CCC, Baltimore, USA  

2018-present, Postdoc Peer Mentor Program, University of Maryland, USA.

2018-present Judge, Undergraduate Poster Competition 2018, Stevenson University and Johns Hopkins Medical Institution, Baltimore, USA.Selected by the Collaborative Teaching Fellows Program to evaluate research posters of undergraduate students.

2019, Judge, 42nd   Medical Research Day (MSRD), University of Maryland, USA.

2020, Judge, 43nd   Medical Research Day (MSRD), University of Maryland, USA.

Links of Interest

Proffered Communications: oral (O) and poster (P) presentation

  1. Morsi H., El Ayoubi H., Moratti E., Vezzalini M., Silvestri G., Stradoni R., Murineddu M., Gabbas A., Monne M. and C. Sorio.  High Resistance Rate of Chronic Myeloid Leukaemia (CML) to Imatinib Myselate (IM) Might be related to Protein Tyrosine Phosphatase Receptor Type Gamma (PTPRG) Down-Regulation. Proceedings Qatar Foundation Annual Research Forum Epub: November 2011 (O).
  2. Bellisola G., Cinque G., Vezzalini M., Silvestri G., Redaelli S., Gambacorti Passerini C., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier Transform InfraRed microspectroscopy (microFTIR) and unsupervised Hierarchical Cluster Analysis (HCA) Proceeding of the Synchrotron Radiation UserMeeting Oxford, UK, September 2012. (P).
  3. Silvestri G*., Mirenda M., Vezzalini M., Moratti E., Laudanna C.and C. Sorio. Molecular mechanisms of the antiproliferative effect of Protein Tyrosine Phosphatase Receptor-like Gamma (PTPRG):  BCR/ABL and LYN kinase as key targets. Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy. Baltimore, Usa, September 2012 (P) (*): recipient of the iCMLF travel award.
  4. Bellisola G., Cinque G., Vezzalini M., Moratti E., Silvestri G., Redaelli S., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy (microFTIR) and unsupervised pattern recognition. Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy. Baltimore, USA, September 2012 (P).
  5. Bellisola G., Cinque G., Sandt C., Dumas P., Silvestri G. and C. Sorio. Oncosuppressive effect of direct transduction of receptor-type tyrosine-protein phosphatase gamma (PTPRG) intracellular catalytic domains in K562 cells. Proceeding of the 15th ESH-iCMLf International Conference on CML Biology and Therapy. Estoril, Portugal, September 2013 (P).
  6. Tomasello L., Silvestri G., Della Peruta M., Fiorini Z., Vezzalini M. and Claudio Sorio. Protein Tyrosine Phosphatase Receptor Type Gamma is an inhibitor of critical BCR/ABL driven pathways in Chronic Myeloid Leukemia. Societa’ Italiana di Cancerologia. Ferrara, Italy, September 2014 (O).
  7. Bellisola G., Tomasello L., Fiorini Z., Silvestri G., Vezzalini M. and Claudio Sorio. Direct transduction of Receptor-Type Protein Tyrosine-Phosphatase Gamma (PTPRG) intracellular catalytic domains in K562 cells. Societa’ Italiana di Cancerologia. Ferrara, Italy, September 2014 (P).
  8. Silvestri G*., Ellis J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Reid A., Milojkovic D., Apperley J., Baer M., Trotta R., and D. Perrotti. MicroRNAs as regulators of stem and progenitor CML cells function. Peer reviewed and printed in the Proceedings of the 2014 ESH-iCMLf International Conference on CML-Biology and Therapy, Philadelphia (O).     (*): Invited Speaker.                                                                      
  9. Silvestri G., Ellis J.J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Roy D-C., Hokland P., Milojkovic D., Reid A., Apperley J.F., Livak F.M., Baer M.R., Trotta R., and D. Perrotti. miR-300 acts as a tumor suppressor in Ph+ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 56th ASH Annual Meeting 2014 (P).
  10. Silvestri G*., Justin Ellis, Lorenzo Stramucci, Jason G Harb, Paolo Neviani, Guido Marcucci, Denis-Claude Roy, Peter Hokland, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M. Livak, Maria R. Baer, Rossana Trotta, and Danilo Perrotti. miR-300 acts as a tumor suppressor in Ph+ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. UMB Cancer Center Retreat, Baltimore, USA, May 18, 2015.(P)                             (*): Best Poster Presentation.
  11. Silvestri G*., Stramucci L, Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C.,  Hokland P., Deininger MW., Bhatia R.,  Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R. and Perrotti D. Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-beta-catenin-modulator miR-300 in leukemic stem/progenitor and NK cell proliferation and survival in CML. Peer reviewed and printed in the Proceedings of the 2015 ESH-iCMLf International Conference on CML-Biology and Therapy, Estoril, Portugal (O).                                                                                              (*): Best scored Biology Abstract.
  12. Silvestri G*., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K.,   Roy D-C,  Hokland P., Deininger MW., Bhatia R.,  Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 57th ASH Annual Meeting 2015 (O). (*): ASH travel award.
  13. Trotta R., Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K.,  Roy D-C., Hokland P., Deininger M.W., Bhatia R.,  Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML.  Proceeding of the AACR Annual Meeting (New Orleans, LA) 2016 (P).
  14. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K.,  Roy D-C.,  Hokland P., Deininger M.W., Bhatia R.,  Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in the Haematologica (Suppl.) dedicated to the European Hematology Association (EHA) Annual Meeting. Copenhagen, Danmark. 2016. (O).
  15. Yu J.E., Silvestri G., Stramucci L., Livak F.M., Baer M.R., Trotta R., and Perrotti, D. The Role of SETBP1 in Leukemia-Initiating Cell Survival and Self-Renewal in Adult Ph+ B-ALL. ESH-iCMLF ESH-iCMLf International Conference on CML-Biology and Therapy, Houston TX Sept. 2016 (O).
  16. Yu J.E., Silvestri G., Stramucci L., Sanada M., Yamaguchi T., Du Y., Westermarck J., Caligiuri M.A., Garzon R., Milojkovic D., Apperley J.F., Roy D-C., Marcucci G., Calabretta, B., Baer M.R., Trotta R. and Perrotti D. Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 –Mediated Suppression of PP2A Activity Peer Reviewed and Published in Blood (Suppl.) dedicated to the 58th ASH Annual Meeting 2016 (P).
  17. P. Burda, N. Čuřík, K. Šrůtová, F. Savvulidi, G. Silvestri, H. Klamová, P. Pecherková, Ž. Sovová, J. Koblihová, T. Stopka, D. Perrotti, K. Machová Poláková Myc-dependent repression mechanism of the mir-150 transcriptional regulation in chronic myeloid leukemia. Peer Reviewed and Published in the Leukemia (Suppl.) dedicated to the European Hematology Association (EHA) Annual Meeting. Madrid, Spain. 2017 (P).
  18. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos  G., May P., Reid A.G., Garzon R.,  Roy D-C.,  Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D.The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. UMB CCC Retreat, September 2017 (P).
  19. Silvestri G*., Stramucci L., Ellis J., Yu J., Harb JG, Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos  G., May P., Reid A.G., Garzon R.,  Roy D-C.,  Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., , Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D.The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. ESH-iCMLf International Conference on CML-Biology and Therapy, Estoril, Portugal Oct. 2017 (O). (*): selected for Key note lecture.
  20. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C.,  Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D.,  Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D.The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 59th ASH Annual Meeting 2017 (O).
  21. Silvestri G., Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R.,  Roy D-C.,  Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. Proceeding of the AACR Annual Meeting, Chicago, 2018 (P).
  22. Trotta R., Silvestri G., Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity. Proceeding of the AACR Annual Meeting Chicago, 2018 (P).
  23. Trotta R., Silvestri G., Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity. JAIDS Journal of Acquired Immune Deficiency Syndromes. 81():63, DOI: 10.1097/01.qai.0000558015.84504.53, April 2019.
  24. Silvestri G. et al. The 14q32.31 MIR300 DLK1-DIO3 oncosuppressor induces CML and AML cancer stem cell quiescence and inhibits NK cell Immunity. 21st ESH-iCMLf International Conference on CML-Biology and Therapy, Bordeaux, France, September. 2019 (O). (*): selected abstract.
  25. Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, Shuzhen Wang, Ann-Kathrin Eisfeld, Bin Zhang, Klara Srutova, Gabriel Pineda, Catriona Jamieson, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Martin Guimond, Peter Hokland, Michael W Deininger, Francesco Dazzi, Dragana Milojkovic, Jane Apperley, Guido Marcucci, Xiaoxuan Fan, Maria R Baer, Bruno Calabretta, Danilo Perrotti. A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer ImmunityBlood, The Journal of the American Society of Hematology. (2019) 134 (Supplement_1): 4141.
  26. Francesca Benedetti*, Giovannino Silvestri*, Saman Saadat, Frank Denaro, Olga S. Latinovic, Harry Davis, Sumiko Williams, Josph Bryant, Chozha V. Rathinam, Robert C. Gallo, Davide Zella. Characterization of a Mycoplasma DnaK Transgenic Mouse. World Microbe Forum, online worldwide, June 2021. *equally contributed.

Editorial Board and Peer review activities for international journals

Editorial Board

  • Review Editor on the Editorial Board of Molecular and Cellular Oncology (specialty section of Frontiers in Oncology and Frontiers in Cell and Developmental Biology)
  • Review Editor  on the Editorial Board of MDPI Journals. https://www.mdpi.com/journal/jcm/submission_reviewers

Peer review activities for international journals 

Ad hoc reviewer with more than 50 articles reviewed since 2017 in over 18 scientific journals including:

  • Genes
  • Cancers
  • Journal of Clinical Medicine
  • Journal of Cellular Physiology 
  • Oncotarget
  • Frontiers in Oncology
  • Healthcare
  • Frontiers in Cell and Developmental Biology
  • Vaccines
  • Pharmaceuticals
  • Blood
  • International journal of cancer
  • Cellular Signaling
  • BioMed Research International
  • Journal of Blood Medicine
  • BioEssays
  • Pathogens
  • International Journal of Molecular Sciences